advertisement
We used antiischemic cardiovascular preparation mildronat as neuroprotective and cytoprotective therapy to treat and prevent glaucomatous optic neuropathy. Prescription of mildronat was given to 35 patients. From 35 patients 20 were women and 15 men, at the age 40-75, visual acuity 0.1-1.0, Pt = 18-24, treatment course 2,5-3 months. Before and after treatment patients were observed with routine methods (visometry, tonometry, determinig visual field on goldman spheroperymeter) and besides that on automated static perimetry Humphrey (30-2; 24-2; Armally) and Medmont studio (Glaucoma test; Full test). Also we used method of biomicroophtalmoscopy by positive lens +83 dptr on slit lamp and described optic nerve head with our scheme. According to the subjective and objective data positive dynamics were signed in 34 patients (63 eyes), negative dynamics in 1 patient (2 eyes). Glaucoma is medical and social problem in many countries. With the difference of expensive methods in prevention and treatment of glaucomatous optic neuropathy, using a mildronat as neuroprotective and cytoprotective drug is available for the majority of glaucoma patients. We recommend using mildronat in patients with primary open angle glaucoma with normolised intraocular pressure and in patients with normal tension glaucoma. LA: Russian
11.8 Neuroprotection (Part of: 11 Medical treatment)